GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts ...

GeneDx has made "important" product improvements to its rapid whole-genome sequencing (rWGS) product in 2024 that should help it unlock genomic testing in the neonatal intensive care unit setting, CEO ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Craig-Hallum analyst William Bonello reiterated a Buy rating on GeneDx Holdings (WGS – Research Report) today. The company’s shares closed yesterday at $85.01. Discover outperforming stocks ...

Management expects GeneDx to report: Revenues of at least $299M for full year 2024, an increase of 54% year-over-year vs previous guidance was $284-$290M. Consensus $288.2M..

Download and save the PDF to your computer Open the downloaded PDF in Acrobat Reader 10 or later Form to be completed by a worker, a payer or an authorized representative to request a ruling as to ...

Microsoft has created a new engineering organization aimed at accelerating AI infrastructure and software development within the company. According to Bloomberg, Jay Parikh, previously VP and ...

STAMFORD, Conn. - GeneDx Holdings Corp. (NASDAQ:WGS), known for its genomic insights in healthcare and having achieved an impressive 2,342% return over the past year according to InvestingPro data, ...

GeneDx Holdings (NASDAQ:WGS) expects to exceed guidance with full year 2024 revenues of at least $299M ($288.20M estimate) and adjusted gross margin of at least 64% (previous guidance was at least ...

Microsoft created a new engineering organization responsible for building its artificial-intelligence platform and tools, CEO Satya Nadella said in an email to employees Monday morning. The new ...